Physician profile
Angel Sanchez
NPI 1225078462
$4,035.95
in general payments reported to CMS, 2019-2025
15 companies · $282 in 2025
The $282 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $138 · 2020: $136 · 2021: $531 · 2022: $2,366 · 2023: $308 · 2024: $275 · 2025: $282.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $866.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $865.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $1,589.79 | 2022-2023 | Januvia, Janumet, Steglujan |
| Janssen Pharmaceuticals, INC | $1,245.60 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $525.81 | 2019-2025 | Lokelma |
| Boehringer Ingelheim Pharmaceuticals, INC. | $174.37 | 2019-2025 | Jardiance |
| Bayer Puerto Rico INC. | $125.63 | 2023-2025 | Kerendia |
| Calliditas Therapeutics US INC. | $78.86 | 2024 | |
| Vifor Pharma, INC. | $65.00 | 2025 | Veltassa |
| Ani Pharmaceuticals, INC. | $64.04 | 2024-2025 | Purified Cortrophin Gel |
| Bayer Healthcare Pharmaceuticals INC. | $53.23 | 2021-2022 | |
| Abbvie INC. | $25.00 | 2022 | |
| Amgen INC. | $22.55 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $18.73 | 2022 | |
| Pbg Puerto Rico LLC | $18.62 | 2019 | |
| Lilly USA, LLC | $14.48 | 2025 | Jardiance |
| Eli Lilly Export S.A. Puerto Rico Branch | $14.24 | 2023 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angel Sanchez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.